Correspondence 0001096906-23-001273 from AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946) (AXIM)
AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946)
Date: June 7, 2023 · CIK: 0001514946 · Accession: 0001096906-23-001273
AI Filing Summary & Sentiment
File numbers found in text: 333-272390
Letter
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E. Suite 114
San Diego, CA 92121
June 7, 2023
VIA EDGAR
Division of Corporation Finance Office of Life Sciences
U.S. Securities & Exchange Commission (the “Commission”)
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jimmy McNamara
Re:
AXIM Biotechnologies, Inc.
Registration Statement on Form S-1
Filed June 2, 2023
File No. 333-272390
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, AXIM Biotechnologies, Inc. (the “Company”) hereby requests that the effective date for the above-referenced Registration Statement on Form S-1 (File No. 333-272390) be accelerated so that it will be declared effective at 5:00 p.m. Eastern Standard Time on Friday, June 9, 2023, or as soon thereafter as is practicable.
The Registrant understands that the Commission will consider this request as a confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes its counsel, John P. Cleary, Esq. of Procopio, Cory, Hargreaves & Savitch LLP, to orally modify or withdraw this request for acceleration. Please contact Mr. Cleary at (619) 515-3221 with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted.
Sincerely,
AXIM BIOTECHNOLOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 June 7, 2023 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission (the “Commission”) 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: AXIM Biotechnologies, Inc. Registration Statement on Form S-1 Filed June 2, 2023 File No. 333-272390 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, AXIM Biotechnologies, Inc. (the “Company”) hereby requests that the effective date for the above-referenced Registration Statement on Form S-1 (File No. 333-272390) be accelerated so that it will be declared effective at 5:00 p.m. Eastern Standard Time on Friday, June 9, 2023, or as soon thereafter as is practicable. The Registrant understands that the Commission will consider this request as a confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes its counsel, John P. Cleary, Esq. of Procopio, Cory, Hargreaves & Savitch LLP, to orally modify or withdraw this request for acceleration. Please contact Mr. Cleary at (619) 515-3221 with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted. Sincerely, AXIM BIOTECHNOLOGIES, INC. /s/ John W. Huemoeller II John W. Huemoeller II President